AU2002241603A1 - Carrier system for specific artery wall gene delivery - Google Patents

Carrier system for specific artery wall gene delivery

Info

Publication number
AU2002241603A1
AU2002241603A1 AU2002241603A AU4160302A AU2002241603A1 AU 2002241603 A1 AU2002241603 A1 AU 2002241603A1 AU 2002241603 A AU2002241603 A AU 2002241603A AU 4160302 A AU4160302 A AU 4160302A AU 2002241603 A1 AU2002241603 A1 AU 2002241603A1
Authority
AU
Australia
Prior art keywords
carrier system
gene delivery
artery wall
specific artery
wall gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241603A
Inventor
Sung Wan Kim
Jae-Woon Nah
Lei Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Publication of AU2002241603A1 publication Critical patent/AU2002241603A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2002241603A 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery Abandoned AU2002241603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24732000P 2000-11-10 2000-11-10
US60/247,320 2000-11-10
PCT/US2001/047072 WO2002042426A2 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery

Publications (1)

Publication Number Publication Date
AU2002241603A1 true AU2002241603A1 (en) 2002-06-03

Family

ID=22934463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241603A Abandoned AU2002241603A1 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery

Country Status (2)

Country Link
AU (1) AU2002241603A1 (en)
WO (1) WO2002042426A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (en) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide
KR20040081418A (en) 2001-09-28 2004-09-21 에스페리온 테라피유틱스 인코포레이티드 Prevention and treatment of restenosis by local administration of drug
FR2835829B1 (en) * 2002-02-13 2007-09-14 Centre Nat Rech Scient NOVEL PROCESS FOR THE PREPARATION OF DNA OR PROTEIN BIOPUCES AND THEIR APPLICATIONS
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
WO2008063157A2 (en) * 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
EP2637689A2 (en) 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN103501806A (en) 2010-11-12 2014-01-08 赛达斯西奈医疗中心 Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
CN110755639A (en) * 2019-11-13 2020-02-07 浙江大学 Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof
CN112226207B (en) * 2020-10-28 2021-10-22 兰州大学 High-stability solid-solid composite phase change material and preparation method thereof

Also Published As

Publication number Publication date
WO2002042426A2 (en) 2002-05-30
WO2002042426A3 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
AU3369900A (en) Gene silencing
AU2001288388A1 (en) Substance delivery system
AU2001273178A1 (en) Stent delivery system
AU7061100A (en) Personal dispensing system
AU5033700A (en) Location enhanced information delivery system
AU4981200A (en) Stent delivery system
AU2002301348A1 (en) Delivery system for cyclopropenes
AU2002325034A1 (en) Stent delivery system
AUPR149200A0 (en) Shelving system
AU2001268879A1 (en) Injection system for gene delivery
AU2001281171A1 (en) Medication dispensing system
AU3884900A (en) Wafer delivery system
AU2002241603A1 (en) Carrier system for specific artery wall gene delivery
AU2133201A (en) Multi-gas delivery system
AUPQ262599A0 (en) Gene expression
AUPQ974300A0 (en) Fluid delivery system
AU7567101A (en) Gene expression system
AU2002222138A1 (en) Drug delivery system
AU1870000A (en) Gene therapy-2
AU6871900A (en) Tsg-like gene
AU1413700A (en) Information delivery system
AU2002210580A1 (en) Drug delivery system
AUPP964899A0 (en) Constructional system
AU2190301A (en) Ranging system
AU4989700A (en) Autism gene